Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125217641 | 12521764 | 1 | I | 20160617 | 20160701 | 20160701 | EXP | AU-BAUSCH-BL-2016-014585 | BAUSCH AND LOMB | PIERUCCI P, MALOUF M, GLANVILLE A, BEAGLEY L, SMITH C, KHANNA R. NOVEL AUTOLOGOUS T-CELL THERAPY FOR DRUG-RESISTANT CYTOMEGALOVIRUS DISEASE AFTER LUNG TRANSPLANTATION. THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2016 MAY;35 (5):685-687. | 56.00 | YR | M | Y | 0.00000 | 20160701 | MD | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125217641 | 12521764 | 1 | PS | GANCICLOVIR. | GANCICLOVIR | 1 | Intravenous (not otherwise specified) | U | 20569 | ||||||||||
| 125217641 | 12521764 | 2 | SS | GANCICLOVIR. | GANCICLOVIR | 1 | Oral | U | 20569 | 450 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125217641 | 12521764 | 1 | Cytomegalovirus infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125217641 | 12521764 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125217641 | 12521764 | Drug ineffective | |
| 125217641 | 12521764 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |